SAN MATEO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference, to be held September 21 - 23, 2009 in New York City.
Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.
Event: UBS Global Life Sciences Conference
Date: Wednesday, September 23, 2009
Time: 4:30 p.m. ET
Place: Grand Hyatt New York, New York City
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 180 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic
Copyright©2009 PR Newswire.
All rights reserved